remains globally common after SARS-CoV-2 infection, with respiratory, fatigue, psychological, and neurological subtypes most often reported.
Evidence
This updated systematic review and meta-analysis pooled 429 studies, estimating global long COVID prevalence at 36% and risk factors including unvaccinated status, pre-Omicron infection, and female sex.
Caveat
The pooled estimates were heterogeneous across populations and measures, limiting direct comparison and pointing to the need for consistent, globally representative follow-up studies.
Simplified
BACKGROUND: This mega-systematic review evaluated the global prevalence of and its subtypes and symptoms, and assessed the effects of risk factors for long COVID.
METHODS: Studies published from 5 July 2021 to 29 May 2024 were searched in PubMed, Embase, and Web of Science, with supplemental updates on 23 July 2024. Data were pooled using a random-effects framework with DerSimonian-Laird estimator. Risk of bias analysis was conducted.
RESULTS: A total of 429 studies were meta-analyzed. The global pooled long COVID prevalence was 36% (95% confidence interval [CI], 33%-40%) with 144 contributing studies. The highest prevalence rates were observed in South America (51% [95% CI, 35%-66%]). The prevalence of long COVID persisted over time, with 35% (95% CI, 31%-39%) at <1 year of follow-up and 46% (95% CI, 37%-57%) at 1-2 years. The most prevalent subtypes were respiratory (20% [95% CI, 14%-28%]) estimated from 31 studies, general fatigue (20% [95% CI, 18%-23%]) from 119 studies, psychological (18% [95% CI, 11%-28%]) from 10 studies, and neurological (16% [95% CI, 8%-30%]) from 23 studies. The 3 strongest risk factors were being unvaccinated for COVID-19 (pooled odds ratio [OR], 2.09 [95% CI, 1.55-2.81]) meta-analyzed from 7 studies, infections from pre-Omicron variants (OR, 1.74 [95% CI, 1.40-2.17]) from 6 studies, and female sex (OR, 1.56 [95% CI, 1.32-1.84]) from 33 studies.
CONCLUSIONS: Long COVID is globally prevalent after a severe acute respiratory syndrome coronavirus 2 infection, highlighting a continuing health challenge. The heterogeneity of estimates across populations argues the need for well-designed follow-up studies that use consistent measures and are globally representative.
Key numbers
36%
Global of
Pooled estimate from 144 studies with confirmed COVID-19 diagnosis.
51%
in South America
Highest observed among regions analyzed.
2.09
for Unvaccinated Individuals
Higher odds of developing compared to vaccinated individuals.
Full Text
We can’t show the full text here under this license.
